ClinicalTrials.Veeva

Menu

Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura

S

Sohag University

Status

Unknown

Conditions

Immune Thrombocytopenic Purpura

Treatments

Diagnostic Test: Laboratory investigations for control
Diagnostic Test: Laboratory investigations for patients

Study type

Observational

Funder types

Other

Identifiers

NCT05093257
Soh-Med-21-10-12

Details and patient eligibility

About

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by bleeding due to isolated thrombocytopenia with platelet count less than 100 × 109/L. ITP is classified based on course of disease into acute (3- <12 months), and chronic (≥12 months). ITP usually has a chronic course in adults whereas approximately 80-90% of children undergo spontaneous remission within weeks to months of disease onset. The main pathogenesis of ITP is the loss of immune tolerance to platelet auto-antigens, which results in increased platelet destruction and impaired thrombopoiesis by autoantibodies and cytotoxic T lymphocytes (CTLs). Platelet autoantibodies, particularly antiglycoprotein (GP) GPIIbIIIa and anti-GPIbIX, are known to cause thrombocytopenia in patients with ITP. As a main component of cellular immunity, T cells play an important role in body defense and peripheral tolerance. Changing number and function of these cells is closely associated with various diseases, including ITP.NK cells can also modulate cellular immunity in ITP patients.

Full description

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by bleeding due to isolated thrombocytopenia with platelet count less than 100 × 109/L.ITP is classified based on course of disease into acute (3- <12 months), and chronic (≥12 months). ITP usually has a chronic course in adults whereas approximately 80-90% of children undergo spontaneous remission within weeks to months of disease onset. The main pathogenesis of ITP is the loss of immune tolerance to platelet auto-antigens, which results in increased platelet destruction and impaired thrombopoiesis by autoantibodies and cytotoxic T lymphocytes (CTLs).Platelet autoantibodies, particularly antiglycoprotein (GP) GPIIbIIIa and anti-GPIbIX, are known to cause thrombocytopenia in patients with ITP. Auto-Abs production often occurs due to the loss of self-tolerance and increased stimulation of the immune system. The immune system includes a variety of B- and T cells which cooperate with each other in T-cell-dependent antibody production reactions and play significant roles in humoral and cellular immunity. Although the pathogenesis of ITP has not been clearly understood, the autoreactive B- and T cells have been directly and indirectly involved in Auto-Abs production, respectively. As a main component of cellular immunity, T cells play an important role in body defense and peripheral tolerance. Changing number and function of these cells is closely associated with various diseases, including ITP. It can be stated that CD4+ T cells are indirectly involved in ITP pathogenesis by inducing the increased activity of B cells during Auto-Abs production. Cytotoxic T lymphocytes (CTLs) are another subgroup of T lymphocytes characterized by the expression of CD8+ surface marker, destroying the pathogenic factors via granzyme and perforin production. These cells are increased in ITP patients and are involved in platelet destruction via augmented production of granzyme and perforin. NK cells can also modulate cellular immunity in ITP patients.

Enrollment

40 estimated patients

Sex

All

Ages

1 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patients with platelet less than 100 × 109/L diagnosed as immune thrombocytopenia according to bone marrow findings .

Exclusion criteria

  • Other causes of thrombocytopenia as:

    • Hypersplenism.
    • Bone marrow diseases including : aplastic anemia, leukemia and myelodysplastic syndromes.
    • Cancer treatments like chemotherapy and radiation therapy.
    • Exposure to toxic chemicals as arsenic and benzene.
    • Medications to treat bacterial infections (antibiotics)and treat seizures or blood thinner heparin.

Trial design

40 participants in 2 patient groups

Group I
Description:
age and sex matched healthy control individuals.
Treatment:
Diagnostic Test: Laboratory investigations for control
Group II
Description:
available number of ITP patients.
Treatment:
Diagnostic Test: Laboratory investigations for patients

Trial contacts and locations

0

Loading...

Central trial contact

Sara M Hashem

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems